Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

(2013) Zejuan Li et al.   JOURNAL OF CLINICAL ONCOLOGY

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

(2012) P. A. Greif et al.   BLOOD

Myeloid malignancies: mutations, models and management

(2012) Anne Murati et al.   BMC CANCER

The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220

(2012) D. Pauwels et al.   HAEMATOLOGICA

An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia

(2011) T Herold et al.   LEUKEMIA

Integrative genomics viewer

(2011) James T Robinson et al.   NATURE BIOTECHNOLOGY

AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

(2010) C Haferlach et al.   LEUKEMIA

CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes

(2009) C. Reindl et al.   CLINICAL CANCER RESEARCH

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia

(2008) S. Hu et al.   MOLECULAR CANCER THERAPEUTICS